Cytophage https://validator.w3.org/feed/docs/rss2.html Cytophage Announces Non-Brokered Private Placement Investors Cytophage Announces Formation of Special Committee of Independent Directors to Evaluate Strategic Alternatives Cytophage Announces Appointment of James Kinley as Chief Financial Officer Cytophage Announces Operational Restructuring Our Team Cytophage Announces Resignation of Director Cytophage Announces Departure of Chief Operating Officer Bird Flu’s Human Risk Spurs Phage Therapy Research Cytophage Announces Closing of Non-Brokered Private Placement and Filing of Q3 Financials Cytophage Announces Closing Date of its Non-Brokered Private Placement Cytophage Announces Closing of First Tranche of Non-Brokered Private Placement Cytophage Identifies Two New Patient Candidates for Phage Therapy for Prosthetic Joint Infections Cytophage Reports Successful Results and Data from Second EU Pilot Study for AviPhage Cytophage Receives Federal Support for Entry into European Market through France Biomanufacturing Mission Cytophage Announces the Commercialization of OvaPhage in Canada Through W.L.T. Distributors Inc. Cytophage secures Health Canada validation for OvaPhage and PhageFend products for use in food safety Une entreprise qui lutte contre la salmonelle avec des virus reçoit l’approbation du fédéral Cytophage Technologies products gain federal OK in fight against salmonella Cytophage Welcomes New Chairman Thomas Wellner and Announces Grant of Options and RSUs Cytophage Enters European Poultry Market with Start of AviPhage Pilot Study Cytophage Announces Development of New Phage-Based H5N1 Vaccine and Advancement Toward Preclinical Trials ‘Ottawa doctor helping to bring back old treatment for new problems’ Cytophage Technologies Reports Positive Outcome from Innovative Bacteriophage Therapy in Patient with Antibiotic-Resistant Infection Cytophage Highlights Existing Phage Solutions to Recent Harmful Bacteria Outbreaks in Food Systems Cytophage Technologies Ltd. Secures Government of Canada New Substance Notification Approval to Facilitate Enterococcus Phage Therapy Trials New Partnership Between Cytophage, Orthopedic Innovation Centre Targets Prosthetic Joint Infections Using Phage Therapy Home Cytophage Named Bioscience Company of the Year by Bioscience Association Manitoba Cytophage Launches Incubator Egg Trials for OvaPhage in Partnership with Leading Canadian Hatchery Frequently Asked Questions ‘Making case for phage therapy prescription’ Swine Bacteriophage Cytophage Announces Closing of Upsized Non-Brokered Private Placement Cytophage Provides Bacteriophages for Landmark Treatment of Joint Replacement Infection in Canada Cytophage Announces Non-Brokered Private Placement Subscribe to learn more. Cytophage Celebrates Opening of State-of-the-Art Phage Production Facility in Winnipeg Cytophage Reports Q3 2024 Financials and Business Update Grand Opening Image Gallery Cytophage Technologies Reports Successful E. Coli Containment in EU Pilot Study for AviPhage Phage Therapy Our Technology Cytophage Announces Mailing of Annual and Special Meeting Materials with Board Nominees Our Story FarmPhage Cytophage Announces Upsizing of its Non-Brokered Private Placement FarmPhage Contact Us News